Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Dr Adam Davenport appointed as CSO to strengthen leadership in integrated drug discovery

We are pleased to announce the appointment of Dr Adam Davenport as Chief Scientific Officer to spearhead our integrated drug discovery offering for biotech and pharmaceutical partners. Bringing over 25 years of hands-on experience in life sciences and partners

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

We are pleased to announce the appointment of Dr Adam Davenport as Chief Scientific Officer to spearhead our integrated drug discovery offering for biotech and pharmaceutical partners.

Bringing over 25 years of hands-on experience in life sciences and partnership management, Dr Davenport’s appointment reinforces the company’s commitment to providing world-class scientific leadership to its collaborators. As an authority in his field, he has authored over 60 patents, publications, and external presentations.

Most recently, Dr Davenport served as Chief Discovery Officer at Proxygen, where he led the development of molecular glue degraders. Prior to joining Proxygen, he led oncology-focused discovery collaborations at Dalriada Drug Discovery, where he served as Chief R&D Officer. His career is also highlighted by almost two decades at Evotec, where he rose to the position of Executive Vice President, Head of Molecular Discovery. He has a PhD in Organometallic Chemistry from the University of Leicester.

Dr Davenport is a seasoned "drug hunter" with an exceptional track record of moving complex programs from initial concept through to clinical evaluation. He has successfully led the discovery of several clinical assets, including P2X3R antagonists, Eliapixant and Filopixant, which achieved Phase 2a Proof-of-Concept in persistent chronic cough. He also discovered the Bradykinin B1R antagonist Fulimetibant that progressed into Phase 2a trials for diabetic neuropathic pain (DNP).

We are delighted to welcome Adam to the team during this period of significant growth for Concept Life Sciences. His passion for science, track record in delivering clinical quality assets, and proven ability to lead multi-disciplinary teams across the UK, Europe, and the US, will be invaluable as we continue to expand our integrated discovery facilities and deliver valuable inflexion points for our global clients." Jonathan Critchley, Interim CEO, Concept Life Sciences

Dr Adam Davenport, Chief Scientific Officer, commented on his appointment: "Concept Life Sciences has built an incredible reputation for scientific excellence and agile project execution. I’m excited to join such a talented team and look forward to supporting customers in effectively navigating the complexities of drug discovery across all modalities to bring the most effective life-changing therapies to patients, more quickly."

As a pioneer in targeted protein degradation (TPD) and covalent drug discovery, Dr Davenport is an expert in innovative modalities. He has specialized knowledge in target classes such as GPCRs, ion channels, kinases, and protein-protein interactions (PPIs). His expertise spans a wealth of therapy areas including pain, oncology, inflammation, women’s health, metabolic disorders and neuroscience.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01ApconiX's in vitro seizure liability assay (iSLA) platform provides a human-relevant approach for assessing seizure liability. Where can AI add the most value alongside assays like this?

There are several areas where AI could add value, but one of the most exciting is helping us translate complex experimental results into actionable insights for drug discovery teams. We see computational and experimental approaches as complementary rather than competing technologies. In vitro assays such as iSLAseizure generate highly relevant biological data, while AI and machine learning can help uncover patterns within that data that might otherwise be difficult to identify. One example is work I recently presented at the BioNow BioAI Symposium, in which we explored the use of structure-activity relationships (SAR) and machine learning models alongside iSLAseizure assay data. Supported by colleagues, including Dr. Louisa Zolkiewski and Dr. Kim Rockley, ApconiX has developed an in-house seizure liability dataset that we analyzed in collaboration with MedChemica. Using machine learning and chemical informatics approaches, we identified chemical substructures that show statistically significant relationships with seizure-related outcomes. The aim is not simply to predict risk, but to understand which molecular features may contribute to that risk and provide medicinal chemists with practical guidance they can apply much earlier in the discovery process. Looking ahead, I think this is where AI can have a particularly powerful impact. Rather than acting as a standalone prediction tool, it can work alongside human-relevant assays such as iSLAseizure to connect molecular structure, experimental biology, and safety outcomes. That combination has the potential to improve decision-making earlier in the discovery process, reduce late-stage safety surprises, and ultimately support the development of safer medicines for patients.

Source: www.news-medical.net ↗
02Could daraxonrasib be effective against other cancer types?

RAS mutations are one of the most common cancer-causing genetic mutations, and the drug is now being studied in several cancer types. I think it's going to work especially well in tumors that are primarily RAS driven, including colon cancer and lung cancer. It might also work in other cancer types in combination with drugs targeting other genetic mutations, but further research is needed.

Source: www.news-medical.net ↗
03How important is it to pick the right target in drug discovery? Could artificial intelligence (AI) be used to aid this process?

Picking the right target is absolutely fundamental. I mentioned that over half of failures of new medicines in development are due to us picking the wrong target. Even if we just doubled our success rate at picking the right target, it would have a huge impact on the development of new medicines for people. One of the reasons, and why I think artificial intelligence could be really important in helping us do that, is that, quite often, there may be some data buried in the literature that tells us a target is really good. Equally valuable is the fact that there may be something buried in the literature that tells you a target is not good. It's much harder to publish negative data than positive data. That target invalidation can be just as valuable as a target validation. It's really about being able to tap into all that knowledge and look up all the facts. That would mean that our systems and other people's AI systems can really be much more effective at picking the right target.

Source: www.news-medical.net ↗
04What supplements really work?

The bulk of vitamins and supplements containing fish oil, biotin, and vitamins A, C, and E can potentially promote nail and hair growth. You can find dietary supplements with higher concentrations of vitamins and minerals that aid skin, hair, and nail health. Fish oil supplements make nails and hair shiny. Fish oil also serves as an agent that can decrease signs of aging. If sun exposure damages the skin, the omega-3 fatty acids in fish oil can help. Biotin, also known as B7, increases hair density and strengthens it. It is found naturally in bananas, eggs, and milk. Vitamins are vital for skin health as well. Vitamin A reduces acne flairs and helps with changes due to aging like wrinkling. A vitamin A deficiency may increase the risk of acne because it becomes difficult for dead skin to slough off hair follicles, blocking pores. Vitamin B lowers the risk of precancerous growths and nonmelanoma skin cancer. Vitamin C is an antioxidant. It leads the fight against free radicals to help stimulate collagen and brighten skin. It also helps to prevent the formation of unneeded melanin that causes uneven skin pigmentation.

Source: www.medicinenet.com ↗
05What are carbs?

Your weight loss plan should keep you healthy and strong as you lose the extra weight. Many plans include a diet low in carbohydrates. Carb cycling is a method of optimizing your carbohydrate intake to meet your needs while dieting, fasting, and working out. When you're carb cycling, you consume carbs to meet your needs on some days and avoid them on other days. The aim of carb cycling is to consume carbohydrates when your body needs them and exclude them at other times. Such strategies in your diet plan can help your weight loss efforts. Carbohydrates, or carbs, are a significant part of the average human diet. Along with proteins and fats, they make up the bulk of your daily meals. Most carbohydrates are broken down by your body into glucose to provide energy for your cells and tissues. Carbohydrates in your diet are of three types — sugars, starches, and fiber. Sugars are simple carbs. Glucose, sugar (sucrose), lactose found in milk, and fructose found in fruits, are naturally occurring sugars. Your body metabolizes these molecules rapidly to yield energy. Starches are complex carbs. They're large molecules that consist of hundreds of molecules of simple sugars joined together. Your body needs to break them down to release energy. Starches are found in bread, potatoes, peas, corn, cereals, and pasta. Fiber is also a complex carbohydrate. Human bodies can't break down these large molecules, so they provide no energy. They're usually excreted as they are in the feces. They add bulk to your meal, so you feel full. Fiber in the diet helps avoid constipation and lowers blood sugar and cholesterol levels. Carbohydrates are an essential part of your diet. A typical diet provides 45% to 65% of its calories from carbohydrates. If you have 2,000 calories a day, you should have about 275 grams of carbohydrates. Always try to choose healthy foods for your carb intake:

Source: www.medicinenet.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →